MEREO BIOPHARMA GROUP PLC (MREO)
Sentynl Therapeutics and Mereo BioPharma Announce Option and License Agreement for alvelestat in Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD)
Sentynl Therapeutics and Mereo BioPharma Announce Option and License Agreement for alvelestat in Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD)
📈 **POSITIVE** • High confidence analysis (84%) • Strong positive business development • Significant competitive advantage **Sentiment:** Positive (95%) **Content type:** Business